A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 12, 2010

Primary Completion Date

June 27, 2012

Study Completion Date

June 27, 2012

Conditions
Colorectal Neoplasms
Interventions
DRUG

CS-1008

CS-1008 was administered once weekly as an intravenous infusion over 30 ± 10 minutes at a dose range of 0.2 to 6 mg/kg. On Days 1 and 36, CS-1008 infusions were radiolabeled with 111\^In (5-7 mCi).

Trial Locations (1)

3084

Ludwig Institute Tumor Targeting Program, Austin Health, Melbourne

Sponsors
All Listed Sponsors
collaborator

Daiichi Sankyo

INDUSTRY

lead

Ludwig Institute for Cancer Research

OTHER